DPP4 and cancer: Testing two DPP-4 inhibitors, saxagliptin and sitagliptin, the researchers found that these inhibitors induced prolonged activation of the NRF2-mediated antioxidant response, leading to overexpression of metastasis-associated proteins, increased cancer cell migration, and enhanced metastasis in xenograft mouse models.